TopoTarget A/S  

(Public, CPH:TOPO)   Watch this stock  
Find more results for TOPO
Jul 31 - Close
CPH real-time data - Disclaimer
Currency in DKK
Range     -
52 week 2.10 - 4.45
Open     -
Vol / Avg. 0.00/602,173.00
Mkt cap 580.52M
P/E 11.30
Div/yield     -
EPS 0.35
Shares 145.79M
Beta     -
Inst. own     -

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 76.68% -419.38%
Operating margin 86.13% -409.55%
EBITD margin - -387.23%
Return on average assets 99.37% -12.85%
Return on average equity 107.54% -14.15%
Employees 12 -
CDP Score - -


c/o Symbion Fruebjergvej 3, Koebenhavn OE

Website links


Topotarget A/S is a Denmark-based biopharmaceutical company focused on the field of oncology. The Company is engaged in the development of cancer therapies, focusing primarily on the development of its principal drug candidate, Belinostat. Belinostat can be used in combination with full doses of chemotherapy, and is in a pivotal trial within peripheral T-cell lymphoma (PTCL) and phase II in cancer of unknown primary (CUP). It works in partnerships with Spectrum Pharmaceuticals Inc., Multimeric Biotherapeutics Inc. and the National Cancer Institute. As of December 31, 2011, the Company had five wholly owned subsidiaries, namely Topotarget UK Limited, Topotarget Germany AG, Topotarget USA Inc., Topotarget Switzerland S.A. and Topotarget Netherlands B.V. The Company�s two largest shareholders are HealthCap funds and Avanza bank. In April 2014, combined holdings of Topotarget A/S shares for all relevant HealthCap entities (HealthCap III and HealthCap IV) were reduced below 10%.